About Translational Intelligence
The Gap Between Bench and Bedside
In medicine, "Translational Science" is the rigorous discipline of turning biological discoveries into life-saving therapies. It is the bridge between the theoretical potential of the lab and the clinical reality of the patient.
We are missing this bridge for Artificial Intelligence.
Today, the biopharma industry is flooded with "Tech AI"—generic advancements from Silicon Valley that do not survive contact with the complex, regulated, high-stakes reality of drug development. We have excess potential, but a deficit of implementation.
Translational Intelligence is the missing discipline. It is the framework for taking computational power and translating it into R&D throughput, clinical success, and operational resilience.
What We Do
This publication is not about the "future of AI." It is about the business of AI modernization right now.
Translational Intelligence is a briefing for the Architects of the future biopharma enterprise—VPs, C-Suite leaders, and Investors who need to move beyond "Pilot Purgatory."
We focus on the "messy middle" of transformation:
- Operating Models: How to structure cross-functional teams that unite data scientists and wet-lab biologists.
- Infrastructure: The buy-vs-build decisions for cloud-native platforms and secure data foundations.
- Governance: Deploying responsible AI in highly regulated environments (FDA, GxP) without stifling innovation.
- Strategy: Moving from ad-hoc use cases to enterprise-wide capability.
Who is Behind This?
Alexander Titus, PhD - Global Head of AI, Enterprise Transformation Leader, & Architect of Bio-Modernization.
I have spent my career at the intersection of machine learning, biotechnology, and national strategy. My work focuses on one thing: getting high-impact systems to work in high-stakes environments.
I led enterprise AI modernization at Avidity Biosciences, architecting the platform and operating model that spans Research, Development, Clinical, Regulatory, Commercial, and G&A functions.
Previously, I have stood at the center of the world's most complex data challenges:
- Google (Public Sector): I led the AI response for the COVID-19 pandemic, deploying secure platforms across 25+ government agencies.
- U.S. Department of Defense: As the Head of Biotechnology Strategy, I directed the modernization portfolio and launched BioMADE.
- National Security Commission on Emerging Biotech: I currently serve as a Commissioner, directing the national strategy for AI/Bio data infrastructure and economic competitiveness.
- Dauntless Venture Capital: As a Co-Founder, I lead technical diligence for deep-tech and national security startups.
- Decycle Biosystems: As a Co-Founder, I helped build a world-class AI-native engineering team for the next generation of industrial chemicals and biomanufacturing.
I hold a PhD in Quantitative Biomedical Sciences from Dartmouth College, and I've been working on AI in biotech since 2015.
Subscription & Membership
Translational Intelligence is the digital publication of In Vivo Group, a premier advisory firm for enterprise transformation.
1. The Briefing (Free)
A monthly high-level analysis of the AI/Bio landscape. Best for industry observers.
2. The Operator’s Playbook (Premium)
Bi-weekly deep dives, downloadable frameworks, and full access to the archive. Best for practitioners and leaders actively building AI functions.
3. The Founding Member Circle (Advisory)
Includes full premium access plus one annual 60-minute strategy session. Designed for executives who need a sounding board for their own transformation roadmap.
Powered by In Vivo Group. Operationalizing the future of science.